CAR-GPRC5D
Phase 1Small molecule
CAR-GPRC5D is one of 12 small molecule programs targeting Plasma Cell Leukemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Plasma Cell Leukemia
#DrugCompanyPhaseTrials
1Alkeran
AApotex Inc.
Approved
Darzalex
Johnson & JohnsonPhase 2
Tecvayli
Johnson & JohnsonPhase 2
Decadron
AAspen Global Incorporated
Phase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Kyprolis
VVirionyx Corporation Limited
Phase 2
Mozobil
GGenzyme, a Sanofi Company
Phase 2
Recombinant Granulocyte Colony-Stimulating Factor
FFred Hutchinson Cancer Center
Phase 2
Anti-BCMA-CAR-T
IInstitute of Hematology & Blood Diseases Hospital, China
Phase 2
BCMA CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CAR-GPRC5D. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details